Pfizer’s TALZENNA and XTANDI cut prostate cancer progression risk by 52%, but who benefits most?
Pfizer wins FDA approval for TALZENNA plus XTANDI in earlier metastatic prostate cancer. See how a 52% progression-risk reduction changes treatment.
Pharma & Biotech
Pharma & Biotech
Pfizer’s prostate cancer combination delivers strong rPFS signal in TALAPRO-3
Talzenna plus Xtandi improved rPFS in HRR-mutated metastatic prostate cancer. Find out what TALAPRO-3 could change next.